Figure S5 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

Key Points

• Refining treatment strategies leads to improved therapy effectiveness, particularly for HR+/HER2- breast cancer patients.
• PD-L1 expression was demonstrated through immunohistochemistry analysis in the multiomics cohort sample.
• Analysis utilized precision medicine methods to inform treatment decisions based on patient-specific factors.
• Tailoring therapies may enhance treatment response and avoid one-size-fits-all approaches in breast cancer care.